DNA testing with Aventa Lymphoma for better diagnosis and treatment: Data & outcomes from clinical leaders
On Demand Webinar
Key takeaways
An integrated approach for evaluating all clinically relevant fusions and rearrangements in B- and T-cell lymphomas:
Accurately diagnose disease and classify subtypes
Refine patient risk assessment to inform treatment decisions
Choose the most effective therapy to optimize outcomes
Meet the speakers
Anthony Schmitt, PhD
Anthony Schmitt, PhD, is the SVP of Science at Arima Genomics, where his expertise in 3D genomics has been pivotal to the company's development of Hi-C technology and its applications in genomics research. He received his PhD from the University of California, San Diego, where he developed novel methodologies for understanding gene regulation using 3D genomics approaches. Since Arima’s inception, Anthony has led the development of the core Arima Hi-C chemistry and technology platform, as well as industry partnerships and academic collaborations.
Russell Ryan, MD
Dr. Ryan is an Assistant Professor of Pathology at the University of Michigan Medical School, where he directs a research lab focused on the biology of lymphoid malignancies and practices clinically as a member of the Hematopathology Service. He earned a B.A. from Amherst College and M.D. from the Yale University School of Medicine, followed by clinical training in Anatomic Pathology and Hematopathology at the Massachusetts General Hospital (MGH). He then completed a postdoctoral research fellowship in the laboratory of Bradley Bernstein at MGH & the Broad Institute. Dr. Ryan’s research focuses on mechanisms that sustain oncogenic gene regulatory programs in B-cell leukemias and lymphomas, with a goal of identifying cancer-specific dependencies that could be exploited for improved patient care. Dr. Ryan has received research funding from the National Cancer Institute, the Leukemia Research Foundation, the V Foundation for Cancer Research, and the American Society of Hematology.
Meet your host
Alex Hastie, PhD
Alex Hastie, PhD, is Vice President, Medical Affairs, at Arima Genomics. Alex’s career has focused on advanced genomic technologies especially for the detection of genetic aberrations in a myriad of diseases. Before Arima, he most recently served as Vice President of Clinical and Scientific Affairs at Bionano Genomics, Inc., where he advanced clinical applications, led clinical studies, and built strong relationships with key opinion leaders to support the company’s clinical goals in rare disease and oncology. Throughout his tenure at the company, he played a crucial role in the company’s innovations and helped to bring optical genome mapping into routine clinical utilization. He holds a PhD in Molecular Biochemistry and Biophysics from the University at Buffalo and completed post-doctoral research at the Max Planck Institute for Biochemistry, in Munich Germany.